Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 118,920 shares of CYTK, which is worth approximately $6.6 Million. The most recent transaction as insider was on Oct 01, 2024, when has been sold 7,300 shares (Common Stock) at a price of $52.1 per share, resulting in proceeds of $380,330. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 119K

10.59% 3M change

23.6% 12M change

Total Value Held $6.6 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 01 2024	SELL Open market or private sale	$380,330 $52.1 p/Share	7,300 Reduced 5.78%	118,920 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.09%	124,220 Common Stock
Sep 17 2024	SELL Open market or private sale	$414,348 $56.76 p/Share	7,300 Reduced 5.69%	120,920 Common Stock
Sep 17 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.97%	128,220 Common Stock
Sep 03 2024	SELL Open market or private sale	$420,961 $57.01 p/Share	7,384 Reduced 5.67%	122,920 Common Stock
Sep 03 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.97%	128,220 Common Stock
Aug 20 2024	SELL Open market or private sale	$410,552 $56.24 p/Share	7,300 Reduced 5.52%	125,004 Common Stock
Aug 20 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.91%	130,304 Common Stock
Aug 07 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.01%	127,004 Common Stock
Aug 06 2024	SELL Open market or private sale	$392,156 $53.72 p/Share	7,300 Reduced 5.57%	123,704 Common Stock
Jul 23 2024	SELL Open market or private sale	$416,246 $57.02 p/Share	7,300 Reduced 5.36%	129,004 Common Stock
Jul 23 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.8%	134,304 Common Stock
Jul 09 2024	SELL Open market or private sale	$408,070 $55.9 p/Share	7,300 Reduced 5.28%	131,004 Common Stock
Jul 09 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.69%	138,304 Common Stock
Jun 25 2024	SELL Open market or private sale	$392,229 $53.73 p/Share	7,300 Reduced 5.2%	133,004 Common Stock
Jun 25 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.69%	138,304 Common Stock
Jun 11 2024	SELL Open market or private sale	$413,075 $53.04 p/Share	7,788 Reduced 5.45%	135,004 Common Stock
Jun 11 2024	BUY Exercise of conversion of derivative security	$43,159 $7.96 p/Share	5,422 Added 3.66%	142,792 Common Stock
May 07 2024	SELL Open market or private sale	$1,012,265 $65.11 p/Share	15,547 Reduced 10.19%	137,056 Common Stock
May 07 2024	BUY Exercise of conversion of derivative security	$94,620 $6.67 p/Share	14,186 Added 8.51%	152,603 Common Stock
Apr 12 2024	SELL Bona fide gift	-	150 Reduced 0.11%	138,417 Common Stock
Apr 09 2024	SELL Open market or private sale	$2,422,877 $74.31 p/Share	32,605 Reduced 19.05%	138,567 Common Stock
Apr 09 2024	BUY Exercise of conversion of derivative security	$190,795 $6.67 p/Share	28,605 Added 14.32%	171,172 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	21,333 Added 13.02%	142,567 Common Stock
Mar 06 2024	SELL Payment of exercise price or tax liability	$542,329 $66.88 p/Share	8,109 Reduced 6.27%	121,234 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM